New pain combo may improve recovery after oral cancer surgery
NCT ID NCT07401641
First seen Feb 13, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This study compares two painkiller combinations—dezocine plus sufentanil versus nalbuphine plus sufentanil—for pain relief after oral cancer surgery with flap reconstruction. Sixty adults will receive one of the two combinations through a patient-controlled pump. The goal is to see which provides better pain control, fewer side effects, and better flap survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTOPERATIVE PAIN MANAGEMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen Universit
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dezocine and nalbuphine (opioid painkillers)
What this could lead to
If it works, this could identify a safer, more effective pain management option for oral cancer patients after surgery.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. The drugs are already approved, so no major breakthrough is expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.